Many Patients Hospitalized for COVID-19 Are Diagnosed With a Sleep Disorder
A team of investigators sought to assess the prevalence of pre-existing sleep disorders and their relationship to disease outcomes in patients with severe COVID-19.
A team of investigators sought to assess the prevalence of pre-existing sleep disorders and their relationship to disease outcomes in patients with severe COVID-19.
Obstructive sleep apnea in young patients results in pathophysiologic changes associated with aging.
Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, improves excessive daytime sleepiness in OSA regardless of primary OSA therapy adherence.
Mask-related side effects have been cited as the most important factor influencing adherence to continuous positive airway pressure (CPAP) therapy.
Investigators assessed the addition of pulse-oximetry to self-reported improvements during hypoglossal nerve stimulation home titration for patients with moderate to severe obstructive sleep apnea.
There may be increased hospitalization risk from influenza infection in patients with obstructive sleep apnea who do not use continuous positive airway pressure.
A study showed that a 4 week intervention of oropharyngeal stimulation and tongue PNF improved cognition, Hba1c and quality of sleep in patients with OSA.
Researchers reviewed COVID-19 literature to determine the relationship between obstructive sleep apnea (OSA) and adverse COVID-19 outcomes.
Patients with sleep apnea who received positive airway pressure therapy did not exhibit reduced cardiovascular risk compared with patients who received usual care.
Researchers analyzed autopsy brain tissue from confirmed obstructive sleep apnea cases for amyloid beta and tau, hallmark proteins of Alzheimer disease.